📋 Tender Overview
A Novel, First-In-Its-Kind, Aptamer-Based Lytacs To Address The Unmet Clinical Need Of Diabetic Wounds.
Ground-Breaking Effort To Treat Diabetic Foot Ulcersdiabetic Foot Ulcers (Dfus) Are A Significant Complication Of Diabetes That Has Proven To Be An Unmet Clinical Condition. Dfus Can Lead To Hospitalisation, Limb Amputation, And Even Death, With A High Recurrence Rate. The Eu-Funded Aptadegrad Project Will Provide A Potential Solution By Developing A Novel Therapy Based On Aptamer Based Lysosome-Targeting Chimaeras (Lytacs) To Heal Dfus. The Therapy Will Target Key Proteins Responsible For Impaired Healing In Diabetic Wounds, Offering A Controlled And Dose-Dependent Reduction Of Mmp-9, Il-1?, And Its Receptor Il-1R1. If Successful, This Project Could Offer A Potential Treatment For Other Types Of Chronic Wounds And Immune Pathologies, With Essential Knowledge Gained About Lytacs For Future Pharmaceutical Development.
Funded Under
The European Innovation Council (Eic)
Total Cost
€ 2 322 037,50
Eu Contribution
€ 2 321 677,50
Coordinated By
Lincbiotech Sociedad Limitada
Spain
Start Date
1 December 2022
End Date
30 November 2027
Objective
Diabetic foot ulcers (DFUs) a major complication of diabetes, occur in ~25% of patients, with a five-year recurrence rate of ~65% .
DFUs often end in hospitalization, with limb amputations in up to 60% of cases . DFU related mortality is 5% within twelve months, rising to 42% after five years. Despite high prevalence and its major impact on the quality of life, no effective treatment has been approved, so DFU remain a highly unmet clinical condition.
APTADEGRAD aims at obtaining in vivo proof-of-concept for a novel, first-in-class therapy using aptamer-based Lysosome Targeted Chimeras (LYTACs) to heal diabetic foot ulcers (DFUs). These LYTACs will target IL-1ß, its receptor IL-1R1, and MMP-9 for degradation, proteins known to play a key role in impaired healing in diabetic wounds. Out hypothesis is that a) aptamer-based LYTACs MoA, may offer the potential to deliver a controlled, dose-dependent reduction of MMP9, IL-1b and its receptor IL-1R1, moderating the excessive DFU inflammatory response, while maintaining biologically beneficial levels of these proteins to promote healing and prevent infection; b) the simultaneous targeting of these relevant proteins will produce a synergetic effect in the inflammation cascade, providing superior efficacy outcomes.
Should the main objective of the project is achieved (i.e. show efficacy in animal models of DFU), we would be showing for the first time a potential therapy based on LYTACs, in this case in the context of diabetic ulcers, with potential applications in other types of chronic wound or immune pathologies. In addition to efficacy data, we will be gathering essential knowledge about LYTACs (toxicity, efficacy, mechanism of action, differences with other approaches such as blocking or inhibition which are essential for successful future transla
